We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Thrombolytic Drug Delivery Device Dissolves Blood Clots

By HospiMedica International staff writers
Posted on 21 Jul 2014
Print article
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).
A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS).

The updated Trellis peripheral infusion system is a pharmacomechanical thrombolysis device that provides a way for physicians to dissolve blood clots resulting from acute deep vein thrombosis (DVT), and before they advance to PTS. The system is comprised of an over-the-wire catheter with two occlusive balloons to close off the treatment area and block drug release to other areas of the body; an infusion zone to deliver the lytic drug; and an oscillation drive unit (ODU) with an integrated dispersion wire to distribute the drug.

The updated system features enhanced drug delivery, increased amplitude of the ODU, and a larger aspiration window than the previous version, which allows for better removal of the drug and the dissolved clot. The system is available in a 6 French catheter size for vessels 3–10 mm in diameter, and an 8 French version for vessels 5–16 mm in diameter. The Trellis peripheral infusion system is a product of Covidien (Dublin, Ireland), and can be used for both arterial and venous peripheral usage.

“Covidien is committed to providing clinicians and patients with advanced technology that is clinically relevant and demonstrates economic value. Our clinical data has demonstrated that the Trellis system’s targeted lytic delivery may reduce the risk of bleeding complications normally associated with systemic thrombolytic infusion,” said Mark Turco, MD, chief medical officer of vascular therapies at Covidien. “Furthermore, intervening in patients with DVT may help improve long-term outcomes in a population that can suffer significant complications if left untreated.”

PTS is a long-term effect of DVT (a condition where a clot develops in one of the body’s deep veins above the knee), and develops when a DVT interferes with the blood flow returning from the leg back to the heart. It can cause lower leg pain and swelling by causing damage to the valves in the veins that normally stop blood from flowing backwards down the leg. PTS occurs in almost half of patients within two years after DVT, and up to 33% of patients with PTS develop ulcers and skin deterioration.

Related Links:

Covidien



Print article

Channels

Business

view channel
Illustration

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.